**Abstract**

**Purpose:** In recent years, research has been reported that dopamine agonists used in the treatment of Parkinson\'s disease have also shown effectiveness in treating patients for depression. We treated animals with the pramipexole (PRM) and observed behavioral changes and changes in the function of the cranial nerves in animal models of learned helplessness. The purpose of the experiment is to investigate the dopamine agonist\'s effect as an antidepressant for depressive states as well as its role regarding the cranial nerves.

**Method:** The experiment included a learned helplessness behavior test, and an assessment of the cranial nerve function using c-Fos immunohistochemistry staining. The learned helplessness model involved a 5-day protocol. The drug was given for four consecutive days, and on the fifth day we measured the number of failed escape attempts using the same method as the second day. The increase or decrease in number of escape attempts was used as an indicator of the drug\'s effectiveness. In order to examine the effect of PRM on cranial nerve activities in learned helplessness, after completion of the test on the fifth day, the brains were collected and any changes to nerve function in the nucleus accumbens, amygdala and hippocampus were assessed using c-Fos immunohistochemistry staining.

**Results and Observations**: In learned helplessness models given a single dose of PRM (1.0mg/kg, i.p.), a significant decrease was observed in the number of failed escape attempts related to learned helplessness behavior. This therefore suggests that PRM, in addition to improving Parkinson\'s symptoms, is a drug that also has antidepressant effects. Furthermore, regarding the parts of the brain affected by PRM\'s antidepressant function, the nerves of the nucleus accumbens shell, central nucleus and basolateral of the amygdala, and dentate gyrus and CA3 regions of the hippocampus were shown to be affected by the antidepressant function.
